Journal: Biology of reproduction

Article Title: Immunolocalization of acidic and basic fibroblast growth factors in porcine uterine and conceptus tissues.

doi: 10.1095/biolreprod56.6.1527

Figure Lengend Snippet: FIG. 1. Western blot analysis of porcine uterine protein extract at Day 12 of gestation. a) Molecular weight markers (x 10 3) (lane 1), total CM-50 sephadex-extracted uterine protein (25 g, lanes 2, 4, and 6), human recombinant bFGF (100 ng, lanes 3 and 5). Lanes 1 and 2 were stained for total protein by colloidal gold stain. Lanes 3 and 4 were in- cubated with anti-bFGF antibody (0.15 Ixg/ml). Lanes 5 and 6 were in- cubated with rabbit IgG (0.15 .Lg/ml). b) Sephadex-extracted uterine pro- tein (25 jIg, stained for total protein by colloidal gold) in nonreducing 7.5-15% PAGE. Bovine aFGF (500 ng, lanes 2, 4, and 6) and sephadex extract (25 g, lanes 3, 5, and 7). Immunoreactive aFGF bands are ob- served in lanes 2 and 3 (incubated with anti-aFGF antibody). The absence of these bands is noted in lanes 4 and 5 (anti-aFGF antibody immunoab- sorbed with bovine aFGF) and in lanes 6 and 7 (incubated with rabbit IgG).

Article Snippet: For aFGE PAGE was performed using 7.5-15% acrylamide gel and bovine aFGF (cat. #132-FA; R&D Systems, Minneapolis, MN) as standard.

Techniques: Western Blot, Molecular Weight, Recombinant, Staining, Incubation

Journal: Anatolian Journal of Botany

Article Title: Protective effects of resveratrol on permethrin-induced fetotoxicity in rats

doi: 10.30616/ajb.1241886

Figure Lengend Snippet: Figure 2. Representative photomicrographs of immuno- histochemical staining of fetal tissues. Immunohistochemical staining for BMP-4 in fetal bone and FGF-1 in fetal lung. In the Perm group, deterioration in the structure of the lacunae and

Article Snippet: In experiments, Perm (Permethrin, 45614, Sigma), Res (Resveratrol, 51852282, Molecula), BMP-4 primary antibody (PA5-19683, Thermo Scientific), FGF-1 primary antibody (sc-7910, Santa Cruz), and Secondary antibody kit (Thermo, Cat. No: 85-9043) were used.

Techniques: Staining, Immunohistochemical staining

Journal: Nutrients

Article Title: Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models

doi: 10.3390/nu16142369

Figure Lengend Snippet: Manuka honey activates AMPK signaling and inhibits mTOR and STAT3 downstream signaling. ( A ) MCF7 cells were treated with increasing concentrations of Manuka honey (0–5%) and 5% Mesquite honey as control. After 24 h, cells were lysed and immunoblotted with specific antibodies. ( B ) MCF7 cells were treated with increasing concentrations of Manuka honey 0.3–5% ( w / v ). After 24 h, cells were lysed, and whole cell extracts were resolved by PAGE and immunoblotted with specific antibodies.

Article Snippet: MCF7 and MDA-MB-231 BC cells were cultured in 6-well plates at a concentration of 250,000 cells/well for 24 h. The next day, cells were treated with either 2.5% MH, 5.0% MH, 5.0% dextrose, 5.0% Mesquite honey, or 10 μM Camptothecin for 24 and 48 h. Cells were collected with AccutaseTM cell dissociation reagent, washed and stained using an Annexin V-FITC and 7-AAD Dead Cell Apoptosis Detection Kit (R&D Systems), and analyzed using flow cytometry.

Techniques: Control

Journal: Cancer Cell

Article Title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

doi: 10.1016/j.ccell.2019.05.013

Figure Lengend Snippet: Transcriptomic CRC Subtypes and CAFs as Drivers of AR to Cetuximab (A) Transcriptomic subtypes in 13 BL and PD biopsy pairs. TA, transit amplifying; SL, stem-like. (B) Volcano plot showing differential expression of growth factors in 5 cases from (A) undergoing CMS2>4 switches. Significance was assessed by paired t test. (C) Changes in TGF-β and EMT transcriptomic signatures through CMS2>4 switches. (D) Changes in fibroblast abundance through CMS2>4 switches based on MCP-counter analysis. (E) Impact of CAF conditioned medium (CM) on the growth of DiFi (left panel) and LIM1215 (right panel) treated with 50 μg/mL CET for 5 days. (F) Western blot analysis showing CAF CM rescue of pERK in DiFi (left panel) and LIM1215 (right panel) treated with 200 μg/mL CET for 2 h. (G) mRNA expression (normalized counts) of growth factors (GFs) (left panel) and their receptors (right panel) in CAF, DiFi, and LIM1215 cells. (H) Growth assay with 200 μg/mL CET and recombinant GF at a concentration of 20 ng/mL (FGF1/2), 10 ng/mL (TGF-β) and 50 ng/mL (HGF) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (I) Western blot analysis of pERK with and without recombinant GF treatment in the presence or absence of 200 μg/mL CET in DiFi (top panel) and LIM1215 (bottom panel). (J) Growth assay with CAF CM and combinations of CET, pan-FGFR inhibitor (FGFRi), and MET inhibitor (METi) for 5 days in DiFi (top panel) and LIM1215 (bottom panel). (K) Western blot analysis of pERK after 2 h treatment with CAF CM and combinations of CET, FGFRi, and METi in DiFi (top panel) and LIM1215 (bottom panel). (E, H, and J) All error bars ± SD of six replicates. See also Figure S4 and .

Article Snippet: Recombinant human FGF1 acidic , RnD Systems , Cat# 232-FA-025.

Techniques: Quantitative Proteomics, Western Blot, Expressing, Growth Assay, Recombinant, Concentration Assay

Journal: Cancer Cell

Article Title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

doi: 10.1016/j.ccell.2019.05.013

Figure Lengend Snippet:

Article Snippet: Recombinant human FGF1 acidic , RnD Systems , Cat# 232-FA-025.

Techniques: Control, Recombinant, Sequencing, Software